Literature DB >> 6342757

Radioimmunodetection of human tumor xenografts by monoclonal antibodies.

D Herlyn, J Powe, A Alavi, J A Mattis, M Herlyn, C Ernst, R Vaum, H Koprowski.   

Abstract

Mouse IgG2a monoclonal antibodies with specific binding reactivity in vitro to human tumors of the gastrointestinal tract were radioiodinated and injected into immunosuppressed mice xenografted with human colon carcinoma tumors. The antibodies preferentially localized in tumor tissue compared to normal mouse tissue, as determined by differential tissue counting of radioactivity. Preferential antibody localization in tumor tissue was greatly enhanced when F(ab')2 fragments of the antibodies were used, and the fragments localized specifically only in those tumors that bind the antibodies in vitro and not in unrelated tumors. Radiolabeled fragments of an anti-hepatitis virus monoclonal antibody of the same isotype as the specific antibody did not localize in tumors. Tumors could be located by whole-body gamma-scintigraphy with radiolabeled specific antibody F(ab')2 fragments without background subtraction.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6342757

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

Review 1.  Immunoscintigraphy for cancer detection: "a thousand ills require a thousand cures".

Authors:  S H de Bie; T C Ferreira; E K Pauwels; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Second antibody for improvement of antibody imaging: liposome-entrapped and free preparations in animal and human studies.

Authors:  H J Begent; K A Chester; K D Bagshawe; P A Keep; F Searle; J Boden; G M Barratt; A J Green; S J Riggs; D F Woodrow
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

3.  Drug localisation and growth inhibition studies of vindesine-monoclonal anti-CEA conjugates in a human tumour xenograft.

Authors:  G F Rowland; R G Simmonds; V A Gore; C H Marsden; W Smith
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  Localization of anti-osteogenic sarcoma monoclonal antibody 791T/36 in a primary human osteogenic sarcoma and its subsequent xenograft in immunodeprived mice.

Authors:  M V Pimm; A C Perkins; N C Armitage; R W Baldwin
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

5.  Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.

Authors:  F Buchegger; C Pfister; K Fournier; F Prevel; M Schreyer; S Carrel; J P Mach
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

6.  Localization of experimental glioma grafts by means of iodinated monoclonal antibodies and radionuclide imaging.

Authors:  D Stavrou; W Mellert; T Bilzer; R Senekowitsch; E Keiditsch; P Mehraein
Journal:  Acta Neuropathol       Date:  1985       Impact factor: 17.088

7.  Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A.

Authors:  Y Haga; C L Sivinski; D Woo; M A Tempero
Journal:  Int J Pancreatol       Date:  1994-02

Review 8.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

9.  Tumor localization of Lewis lung carcinoma with radiolabeled monoclonal antibodies.

Authors:  P Midoux; T Maillet; F Thérain; M Monsigny; A C Roche
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

10.  Detection of a circulating gastrointestinal cancer antigen in sera of patients with gastrointestinal malignancies by a double determinant immunoassay with monoclonal antibodies against human blood group determinants.

Authors:  M Herlyn; J W Shen; H F Sears; C I Civin; H L Verrill; E M Goldberg; H Koprowski
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.